{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:44:02Z","timestamp":1784547842801,"version":"3.55.0"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> In the absence of reliable data on drug-resistant TB in Eritrea, a national survey was conducted in 2018 using molecular-based methods, bypassing the need for culture.<jats:bold>METHODS:<\/jats:bold> A cross-sectional study was conducted in all 77 TB microscopy centres in the\n country. All 629 newly registered sputum smear-positive pulmonary TB patients were enrolled over 12 months. Sputum samples were tested using the Xpert<jats:sup>\u00ae<\/jats:sup> MTB\/RIF assay and targeted next-generation sequencing (Deeplex Myc-TB) to identify resistance and explore the phylogenetics\n of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> complex strains.<jats:bold>RESULTS:<\/jats:bold> Drug resistance profiles were obtained for 555 patients (502 new, 53 previously treated). The prevalence of rifampicin-resistant TB (RR-TB) was respectively 2.0% and 7.6% among new and previously treated cases. All RR-TB\n isolates that were susceptible to isoniazid displayed a phylogenetic marker conferring capreomycin resistance, confirming circulation of a previously described resistant TB sub-lineage in the Horn of Africa. Only one case of fluoroquinolone resistance was detected.<jats:bold>CONCLUSION:<\/jats:bold> The\n prevalence of rifampicin resistance among TB patients is encouragingly low. The scarcity of fluoroquinolone resistance bodes well for the success of the recommended all-oral treatment regimen. Surveillance based on molecular approaches enables a reliable estimation of the burden of resistance\n and can be used to guide appropriate treatment and care.<\/jats:p>","DOI":"10.5588\/ijtld.20.0558","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T04:40:17Z","timestamp":1609476017000},"page":"43-51","source":"Crossref","is-referenced-by-count":20,"title":["First molecular-based anti-TB drug resistance survey in Eritrea"],"prefix":"10.5588","volume":"25","author":[{"given":"A. B.","family":"Mesfin","sequence":"first","affiliation":[{"name":"Communicable Diseases Control Division, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Z.","family":"Araia","sequence":"additional","affiliation":[{"name":"Communicable Diseases Control Division, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. N.","family":"Beyene","sequence":"additional","affiliation":[{"name":"Communicable Diseases Control Division, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Mebrahtu","sequence":"additional","affiliation":[{"name":"Communicable Diseases Control Division, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. N.","family":"Suud","sequence":"additional","affiliation":[{"name":"National Health Laboratory, Ministry of Health, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. M.","family":"Berhane","sequence":"additional","affiliation":[{"name":"National Health Laboratory, Ministry of Health, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. T.","family":"Hailu","sequence":"additional","affiliation":[{"name":"National Health Laboratory, Ministry of Health, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Z.","family":"Kassahun","sequence":"additional","affiliation":[{"name":"Eritrea Country Office, World Health Organization, Asmara, Eritrea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. T.","family":"Auguet","sequence":"additional","affiliation":[{"name":"Global TB Programme, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Dean","sequence":"additional","affiliation":[{"name":"Global TB Programme, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Cabibbe","sequence":"additional","affiliation":[{"name":"Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2021\/00000025\/00000001\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T15:06:26Z","timestamp":1632495986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.20.0558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["1027-3719(20210101)25:1L.43;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.20.0558","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}